BioNTech founders to contribute to book documenting how they developed first COVID-19 vaccine
Drs Sahin and Türeci will explain the 30 years of scientific research that laid the foundations for the first COVID-19 vaccine, the publisher St Martin’s said.

New York: The husband and wife team who helped make the first COVID-19 vaccine are contributing to a book about their efforts. BioNTech founders Ugur Sahin and Özlem Türeci are collaborating with Joe Miller of the Financial Times on The Vaccine, St Martin’s Publishing Group announced on 8 June.
Publication is scheduled for 2 November. That’s one week before a book by the head of Pfizer, which teamed up with the Germany-based BioNTech to develop the vaccine, is scheduled to come out.
“The Vaccine will reveal how they were able to develop a panel of vaccine candidates within a matter of weeks, how they convinced major pharmaceutical companies to support their work, how they navigated negotiations with the US administration and the European Union, and how in partnership with Pfizer they managed to produce more than two billion doses for countries around the world,” according to St Martin’s.
“Drs Sahin and Türeci will explain the 30 years of scientific research that laid the foundations for the first COVID-19 vaccine, at a time when public confidence in its safety and efficacy is crucial to offering humanity a route out of this pandemic. And, they will offer a glimpse into the potential treatment of other diseases that the success of the BioNTech vaccine offers.”
Pfizer Chairman and CEO Albert Bourla is also working on a book, announced last month. Harper Business is publishing Bourla’s Moonshot: Inside Pfizer’s Nine-Month Race to Make the Impossible Possible on 9 November.
Pfizer last December became the first US company to have a vaccine authorized by the FDA, which days later approved a vaccine by Moderna and in February one by Johnson & Johnson.
also read

Antony Blinken calls for increased vaccine production capacity globally
Joe Biden had announced that the US will share 75 percent of unused COVID-19 vaccines from its stockpile with countries through COVAX

Centre says no decision on granting indemnity to COVID-19 vaccine manufacturers yet
NITI Aayog's VK Paul said the issue has come up in the context of foreign companies, specifically Pfizer, and that the Centre is discussing the issue with the company

COVID-19 vaccine: SC questions Centre over policy of mandatory registration on CoWIN, flags 'digital divide'
The apex court bench headed by DY Chandrachud also stated that the policy makers must have an 'ear to the ground' and make the process accessible to all